Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

• Published in: The New England journal of medicine Vol. 367; no. 13; pp. 1187 - 1197
• Main Authors: Scher, Howard I, Fizazi, Karim, Saad, Fred, Taplin, Mary-Ellen, Sternberg, Cora N, Miller, Kurt, de Wit, Ronald, Mulders, Peter, Chi, Kim N, Shore, Neal D, Armstrong, Andrew J, Flaig, Thomas W, Fléchon, Aude, Mainwaring, Paul, Fleming, Mark, Hainsworth, John D, Hirmand, Mohammad, Selby, Bryan, Seely, Lynn, de Bono, Johann S
• Format: Journal Article
• Language: English
• Published: Waltham, MA Massachusetts Medical Society 27.09.2012
• Subjects: Aged; Androgen Receptor Antagonists - adverse effects; Androgen Receptor Antagonists - therapeutic use; Androgen receptors; Androgens; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Castration; Chemotherapy; Clinical trials; Diarrhea; Disease-Free Survival; Docetaxel; Double-Blind Method; Fatigue; General aspects; Gynecology. Andrology. Obstetrics; Humans; Kaplan-Meier Estimate; Male; Male genital diseases; Medical sciences; Men; Metastases; Middle Aged; Multivariate Analysis; Neoplasm Metastasis - drug therapy; Nephrology. Urinary tract diseases; Orchiectomy; Pain; Phenylthiohydantoin - adverse effects; Phenylthiohydantoin - analogs & derivatives; Phenylthiohydantoin - therapeutic use; Prostate cancer; Prostate-specific antigen; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - mortality; Prostatic Neoplasms - surgery; Seizures; Seizures - chemically induced; Signal transduction; Signal Transduction - drug effects; Survival; Taxoids - therapeutic use; Testosterone; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Medicine; Chemotherapy; Urinary system disease; Treatment; Prostate disease; Malignant tumor; Male genital diseases; Prostate cancer; Survival; Cancer

In a study involving nearly 1200 men with metastatic prostate cancer who had progressive disease after chemotherapy, enzalutamide, a novel androgen-receptor blocker, extended the median survival by nearly 5 months, as compared with placebo (18 months vs. 13 months). Prostate cancer is an androgen-de...